Gilead registers two Phase 2 trials: PBC combo study and weekly oral HIV regimenSep 25Weekly roundup, 2 itemsGilead SciencesGS-3242
King's College Hospital registers PK study of Gilead-partnered TAF regimen in kidney diseaseSep 10Trial updateemtricitabineGilead Sciences
NIAID-led IMPAACT 2026 pharmacokinetic study terminated early, results postedAug 26Trial updateGilead SciencesGlaxoSmithKline
Kite's ZUMA-2 Cohort 3 trial in BTKi-naive mantle cell lymphoma completes, results postedAug 18Trial updatebrexucabtagene autoleucelFludarabine
Vanderbilt registers Phase 2 Lazarus trial testing IT therapy to prevent ICANS after CAR TAug 13Trial updateGilead Sciences
NJCRI registers transgender liver health study with Gilead as collaboratorAug 5Trial updateGilead Sciences
Gilead reports Q2 2026 results with three FDA approvals, three positive Phase 3 readoutsAug 4Quarterly updateGilead Sciences
FINCH 4 filgotinib RA extension study completes, results posted after long-term runJul 27Trial updateGilead Sciences
Gilead's GS-0415 recruiting in Phase 1 HIV trial testing SC/IV dosingJul 22Trial updateGilead SciencesGS-0415
Gilead registers Phase 2/3 HIV combo trial and Phase 1 oncology study for GS-1206Jul 16Weekly roundup, 2 itemsGilead SciencesGS-1206
Gilead registers two Phase 3 trials of lenacapavir long-acting regimen with TAB and ZABJul 6Weekly roundup, 2 itemsGilead Scienceslenacapavir
Gilead's Phase 2 obeldesivir RSV trial terminated by sponsor; results postedJun 30Trial updateGilead Sciencesobeldesivir
Sign in